A phase III multicenter clinical trial of Analatro® [antivenin latrodectus (black widow) equine immune F(ab)2] in patients with systemic latrodectism,
Role: PI,
Instituto Bioclon S.A.,
(12/2013 - 12/2014)
Status: Completed
Systemic Review of Patients with Coronavirus Disease 2019 (COVID-19) Treated at Loma Linda University Medical Center Emergency Department,
Role: Investigator,
LLU Dept. of Emergency Medicine,
(04/2020)
Status: Approved